Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CStone Pharma Completes Record-Breaking $260 Million B Financing

publication date: May 9, 2018

CStone Pharma of Suzhou raised $260 million in a Series B financing, which the company claims is the largest Series B round for any China biopharma. A two-year-old company, CStone has now raised $410 million to support its ambitious portfolio of ten immuno-oncology candidates. The company is focused on discovering new combinations of drugs that address cancers with high incidence in China. The B round was led by GIC Private Limited, Singapore's sovereign wealth fund, and joined by a list of well-known new and existing investors. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital